The Lancet Respiratory Medicine
Издатель: Elsevier · ISSN 2213-2600 · 54 статей
- 2027 GOLD COPD report
- Children are not small adults: CAD for childhood tuberculosis
- Closing the logic gap—expanding who we consider for tuberculosis treatment
- Risk factors for hospital admission and mortality in patients with influenza virus infection: a systematic review and meta-analysis
- The early life window of opportunity for correcting organ dysfunction in people with cystic fibrosis
- Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in children with cystic fibrosis aged 2–5 years (TIMBERLINE Trial VX21-121-105): a phase 3, open-label study
- Global hospital admission and case fatality risks among patients with influenza virus infection: a systematic review and meta-analysis
- Lung cancer: sharing progress in an equitable way
- NEWS2 and the timing of antibiotics in suspected sepsis
- From the cost of asthma to the economic dividends of asthma control
- Survival is not the end(point): the second phase of ECPR care
- Identifying the residual unmet need in severe asthma
- Unravelling of tuberculosis control in Ukraine
- NEWS2 versus shock status to stratify antibiotic urgency in patients with suspected sepsis: a retrospective, multicentre cohort study
- Global economic burden attributable to asthma, 2025–50: a global modelling analysis of 154 countries and territories
- Symptom burden to characterise, predict, and prevent asthma attacks: a patient-level meta-analysis of randomised trials and translational prospective studies
- Cryobiopsy versus conventional bronchoscopic sampling for peripheral pulmonary lesions (Cryo-RCT): an open-label, parallel-group, randomised trial
- Early-stage non-small-cell lung cancer: emerging treatments and evolving challenges
- Targeted therapies in advanced non-small-cell lung cancer: new biomarkers and treatment strategies
- Amivantamab, lazertinib, and bevacizumab: a chemotherapy-free option for patients with advanced EGFR-mutant NSCLC with acquired resistance to a third-generation EGFR TKI
- Combined amivantamab, lazertinib, and bevacizumab in patients with EGFR-mutant advanced non-small-cell lung cancer with acquired resistance to a third-generation EGFR tyrosine-kinase inhibitor (ETOP 18-21 AMAZE-lung): a prospective, international, multicentre, single-arm, phase 2 trial
- South Africa shifts away from salbutamol-only asthma relief
- When a vulnerable lung meets a changing climate
- Interstitial lung diseases in a changing climate: emerging risks and opportunities to improve care
- Efzofitimod versus placebo in patients with pulmonary sarcoidosis (EFZO-FIT): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- Corticosteroid reduction and the endpoint challenge in sarcoidosis: striving for the lowest dose of uncertainty
- Long-term safety and efficacy of twice-yearly depemokimab in type 2 asthma with an eosinophilic phenotype: 2-year integrated analysis of the phase 3a SWIFT-1 and SWIFT-2 studies and AGILE open-label extension
- Twice-yearly depemokimab: beyond dosing convenience
- The present and future of chronic obstructive pulmonary disease prevention, diagnosis, and management in China: a Lancet Respiratory Medicine Commission
- From coverage to equitable reach: addressing social inequalities in COPD in China